Novo Nordisk (NYSE: NVO)
Q3 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-11-02 | ||||||
REV |
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | 0.820 | 0.840 | 0.0200 | ||||
REV | 5.810B | 5.912B | 102.000M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Novo Nordisk (NYSE: NVO) through any online brokerage.
Other companies in Novo Nordisk’s space includes: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Novartis (NYSE:NVS), Roivant Sciences (NASDAQ:ROIV) and Pfizer (NYSE:PFE).
The latest price target for Novo Nordisk (NYSE: NVO) was reported by UBS on Tuesday, June 28, 2022. The analyst firm set a price target for 0.00 expecting NVO to fall to within 12 months (a possible -100.00% downside). 6 analyst firms have reported ratings in the last year.
The stock price for Novo Nordisk (NYSE: NVO) is $103.215 last updated August 5, 2022, 7:59 PM UTC.
A quarterly cash dividend of $1.04 per share of Class A Common Stock. The quarterly cash dividend was payable on April 5, 2022 to stockholders of record on March 25, 2022.
Novo Nordisk’s Q3 earnings are confirmed for Wednesday, November 2, 2022.
There is no upcoming split for Novo Nordisk.
Novo Nordisk is in the Health Care sector and Pharmaceuticals industry. They are listed on the NYSE.